A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
Launched by HOFFMANN-LA ROCHE · Oct 16, 2007
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • post-menopausal women, 50-85 years of age;
- • any inflammatory rheumatoid disease including polymyalgia rheumatica;
- • receiving treatment with 5-15 mg/day of prednisolone.
- Exclusion Criteria:
- • previous treatment with an iv bisphosphonate at any time;
- • previous treatment with an oral bisphosphonate within the last 6 months, \>1 month of treatment within last year, or \>3 months of treatment within last 2 years;
- • treatment with parathyroid hormone in last 2 years;
- • inability to stand or sit in an upright position for at least 60 minutes;
- • inability to swallow a tablet whole;
- • history of major gastrointestinal disease.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oulu, , Finland
Kuopio, , Finland
Helsinki, , Finland
Turku, , Finland
Lahti, , Finland
Tampere, , Finland
Vantaa, , Finland
Hyvinkää, , Finland
Jyväskylä, , Finland
Hämeenlinna, , Finland
Jyvaeskylae, , Finland
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials